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Stimuli-responsive liposome systems that utilize endogenous triggers of tumor 
microenvironment have generated great attention in recent drug delivery research.  Among such 
formulations, redox-responsive liposomes seem highly promising for cancer treatment due to 
their potential to release high drug concentrations upon reduction (by reductase enzymes).  
The research described in this thesis involved the evaluation of kinetics of trimethyl-lock 
quinone propionic acid reduction and lactonization,	  which accounts for payload release from 
trimethyl-lock quinone propionic acid-decorated liposomes.  To achieve the ultimate goal of this 
research, several trimethyl-lock quinone propionic acid-based amide compounds were 
synthesized and characterized.  Kinetic studies were carried out with 1H NMR spectroscopy 
under different experimental conditions, and time-resolved 1H NMR spectra were used to 
evaluate the kinetic rate constant (k) and half-life time (t½) values for the lactonization 
(cyclization) reaction. 
Upon reduction, five different quinone ring-substituted quinone propionic acid-
ethanolamine derivatives have shown distinct cyclization rates, representing the influence of ring 
substituent on lactonization.  Tertiary amides, and organic solution conditions, slow down the 
cyclization process, whereas buffer conditions and higher temperature enhanced the trimethyl-
lock lactonization.  The outcome of this research can be utilized to optimize redox-responsive 
trimethyl-lock quinone propionic acid based liposomes, as well as other effective target delivery 








1.1 Research Goals and Aims 
The goal of this research is an investigation of the kinetics associated with the reduction and 
lactonization of trimethyl-lock quinone propionic acid derivatives for potential application in 
liposome drug delivery systems.  In particular, kinetics of quinone reduction followed by its 
lactone formation with different amide structures, as well as substituents on the quinone ring, 
under various experimental conditions (temperature, pH, buffer, and solvent) will be 
investigated.  
After the discovery of spontaneous formation of closed bilayered structures of phospholipids 
in aqueous medium by Alec Bangham, liposomes have developed enormously due to their 
versatile supramolecular architecture.1-3  They have piqued an extensive interest during the last 
decades as a pharmaceutical carrier because of their attractive biological properties, such as 
biocompatibility, low toxicity, biodegradability, and amphiphilicity.3  In addition, their 
amphiphilic architecture provides the opportunity to enclose both hydrophobic and hydrophilic 
active pharmaceutical ingredients (API).1  In 1995, the U.S. Food and Drug Administration 
(FDA) approved the first liposomal drug formulation, Doxil, doxorubicin encapsulated in 
poly(ethyleneglycol), PEG, liposomes, for the treatment of Kaposi sarcoma and eventually it was 
accepted for ovarian, and metastatic breast cancers.1,4  Since then, several liposomal drug 
formulations were developed and introduced to the market.  To date, 11 liposomal drug 
formulations have been clinically accepted and 6 more are under clinical evaluation.4  Moreover, 
liposomal applications are well established in several other areas, including gene delivery, 
sensors, immunoassays, microfluidics, and separations etc.2,5-7 
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At present, conventional liposomes are used in some therapeutic applications, but their utility 
is problematic due to their instability, inefficient drug accumulation, and harmful toxic side 
effects to normal healthy tissues.8  Furthermore, they encounter fast elimination from the blood 
stream and are captured by the mononuclear phagocyte system (MPS) before entering the target 
site.1,9  In order to thwart these issues, research has been moved a long way to develop novel 
liposomal frameworks which can be optimized to have an efficient targeting and payload release. 
To date, several new liposomes have been developed, but they still carry limitations, such as 
stability and toxicity. Nevertherless, efforts continue to be made to optimize these systems.1,3,10 
 One possible method that can be used to achieve selective targeting and efficient drug 
accumulation involves the development of stimuli-responsive liposomal system by using 
environmental triggers that are prominent at the targeted site of delivery.  In response to the 
internal stimulus, they are expected to release their cargo in a selective and controllable manner, 
thereby improving drug efficacy and minimizing side effects.1,3,8,11,12  To date, the McCarley 
research group has developed a redox-triggerable liposome system based on a trimethyl-lock 
quinone propionc acid attached to a lipid.  This liposome system dissembles upon reduction of 
the trigger moiety (quinone) that provokes the subsequent lipid detachment to release of 
liposome payload to the external environment.8,11,12 However, the kinetics of trigger 
disintegration from the lipid remains unexplored under different buffer, pH, solvent, and 
temperature conditions. 
The first aim of this research is the synthesis of model trimethyl-lock quinone propionic acid-
amide derivatives for kinetic studies.  The potential of quinone reduction, as well as the rate of 
amide cleavage from the model compounds, are assumed to be similar to corresponding quinone-
lipids in liposomes since the distance to any functional moiety at the end of the propionic acid 
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side chain is far off from the quinone head group to have any electronic impacts.11  However, 
investigating how the different substituents on the quinone ring affect the kinetics of trigger 
cleavage is essential.  Therefore, different types of quinone propionic acid-amide derivatives 
were synthesized and characterized.  
The second aim of this research is to investigate the lactonization kinetics of trimethyl-lock 
quinone propionic acid-amide derivatives under different environmental conditions.  In response 
to that, influence of temperature, solvent, and buffer conditions were studied. The reduction and 
lactonization of the compounds were followed by 1H NMR spectroscopy upon addition of a 
chemical reducing agent, sodium dithionite (Na2S2O4), under anaerobic conditions.  
The encapsulated cargo of the liposome will be delivered with the activation of the quinone 
via either chemical or enzymatic reduction, making possible to use liposomes made up of lipids 
processing a specific quinone trimethyl-lock head group as reagent carriers.  The findings here 
contribute to the development of a redox-responsive liposomal formulation having a favorable 
kinetic payload release profile under appropriate environmental conditions. 
1.2  Nanoparticle Drug Delivery Systems 
1.2.1 Motivation  
An exciting new direction in drug delivery is the development of biocompatible and 
biodegradable pharmaceutical carriers capable of precise drug release to a specified target at a 
given time.9,13  One possible approach is the miniaturization of the delivery systems through 
advances in nano-biotechnology.14  So far, various nanoscaled pharmaceutical drug delivery 
devices have been developed and are in diverse stages of investigation to meet up the challenges 
in drug delivery. 9,14-16 
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Nanoscaled drug carriers are “integrated functionalized nanostructures” having 
fascinating properties due to their “spatial and temporal organization, coordination and 
regulation of action of individual components.”9  They can be optimized so as to alter their 
pharmacokinetics, such as favorable absorption, distribution, metabolism, and excretion 
(ADME) compared to free drug.  Due to their diminutive size and high surface-to-volume ratios, 
their rates of dissolution are enhanced and are able to penetrate across the capillaries into cells to 
permit the efficient accumulation.9,14,15  Moreover, opzonization of these with opsonins such as 
fibrinogen, IgG ant, and protein C3b prevents the rapid clearance by the reticuloendothelial 
system (RES).  Thus thereby promoted active or passive targeting.9  These properties increase 
the therapeutic agent’s stability and pharmacokinetics, while reducing the harmful side effects to 
healthy cells.  
Most of the recent research focus toward the nanoparticulate pharmaceutical carriers in 
order to apply for challenging, long-lasting diseases such as HIV, cancer, and diabetes.14  Among 
these, cancer gains greater attention because of its complex nature of treatment.  Current 
therapies for cancer are not universally effective due to lower therapeutic index and poor 
selection between healthy and cancer cells.  One of the most promising tactics to overcome this 
challenge is the use of nanocarriers where chemotherapeutic agent is encapsulated and is then 
dissembled at the tumor site, which thereby improves site-specific toxicity.14  In addition, Cui 
and co-workers have reported a nanoparticulate vaccine delivery system wherein peptide antigen 
is encapsulated for immunization.  Even though this methodology provides attractive platform 





1.2.2 Types of Engineered Nanopartcles in Drug Delivery 
 The immense interest has surrounded the area of new delivery systems based on the state-of-
the-art nanotechnology owing to the emerging development of nanotechnology in the past few 
decades.14  They are considered as smart candidates for transporting therapeutic agents to the 
targeted sites.14  To date, a variety of nanoengineered drug delivery systems are available, and 
only a few selected systems are discussed here.  
Polymeric nanoparticles are either nanospheres or nanocapsules depending on their structure 
and offer distinct advantages over other nano-systems in terms of efficiency and effectiveness.9,15	  	  
They are highly stable and able to deliver therapeutic agents at a higher concentration due to 
their variable surface charge.15  “Drug encapsulation and absorption, biodistribution pattern, 
elimination, and drug release are affected by various factors, including polymer composition, 
hydrophobicity, surface charge, biodegradation profile of the nanoparicles”.15  In order to 
achieve the desired biodistribution, most of them are modified with different targeting moieties 
such as PEG molecules, folic acids, avidin, and biotin, etc.  Some known polymers used to 
prepare these types of nanoparticles are: poly(D, L-lactide), poly(lactide-co-glicolide), 
poly(cyanoacrylates), poly(anhydride) etc.9  These are potential drug carriers for cancer, 
diabetes, transplant rejection and schizophrenia therapies. 9,14,15 
Polymer drug conjugates and polymeric micelles are other forms of nanoscale polymeric 
structures that are stable under biological environments.  Polymer drug conjugates are hybrid 
architectures that merge a bioactive agent with a water-soluble polymer (natural or synthetic) in a 
covalent manner to ensure proper transport to the desired site.  Once it goes to the targeted site, 
the polymer-drug link dissembles, and the active form of the drug is released into the medium.9 
Polymeric micelles are typically formed by amphiphilic block copolymers (20–50 nm), which 
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are comprised of a hydrophobic core and a hydrophilic corona.  They are highly stable, 
biodegradable, biocompatible, and possess a small consistent size distribution, extending their 
circulation time in the blood stream.9  Furthermore, polymeric micelles possess very low critical 
micelle concentration (CMC) and are susceptible for active targeting via modifications.9,18,19   
Dendrimers are compact artificial macromolecules, composed of a central core, internal 
branches, and end groups in a symmetric three dimensional architecture.  This unique 
organization allows creating a controlled, mono-dispersed, nano-sized sphere that possesses a 
hydrophobic interior with multiple attachment sites.15,20  This feature facilitates bioactive agents 
to be chemically attached or encapsulated or physically adsorbed on to the dendrimer surface 
according to its application.9  So far they have been used to carry a number of low molecular 
weight drugs (5-fluorouracyl and nifedipine), DNA, and imaging agents (gadolinium) for the 
diagnosis and treatment of cancer.9 
Liposomes are extremely versatile, self-closed structures formed by one or more concentric 
lipid bilayers with a hydrophilic interior and a hydrophobic exterior.1,2  The hydrophobic lipid 
bilayers provide room for the hydrophobic active pharmaceutical ingredients (APIs), while the 
aqueous interior can host hydrophilic APIs.  They offer several advantages over other nano-
carriers due to their size, amphiphilic nature, and molecular framework, and are also the first 
nanocarrier which came into the market.1,11,21  Liposomes can entrap a wide variety of API as 
well as larger doses of them due to their micro to nanometer size.  The encapsulation protects 
APIs from destructive entities inside the body and facilitates delayed release which is 
advantageous for minimizing the toxic effects and maximizing the therapeutic index.5   
Liposome research has been progressed extensively from first-generation to third-generation 
materials in the last few decades.9  The conventional or first-generation liposomes protect their 
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payload from degradation, while allowing for passive targeting to tissues or organs (spleen, bone 
marrow, liver).  However, their higher uptake by the reticuloendothelial system (RES) that leads 
to their removal from the blood circulation system led research towards the second generation of 
liposomes, which are primarily obtained by inclusion of a protective polymer, poly(ethylene 
glycol), to the liposomal composition. 9  Consequently, stable, long-circulating “stealth” 
liposomes have been developed and have an increased accumulation at the pathological sites via 
the enhanced permeability and retention effect (EPR).3,9,22  This effect is beneficial for 
chemotherapy23 because liposomes need to reach and stay for an extended time period at the 
tumor sites in order to achieve proper drug release.  As a result, liposome research had as its 
preliminary focus on cancer treatment, and the U.S. FDA approved the first chemotherapeutic 
liposomal drug formulation, Doxil, in1995 for the treatment of Kaposi sarcoma, ovarian, and 
metastatic breast cancers.1,4 DaunoXome and Myocet are other commercially-available 
chemotherapeutic liposomal formulations, while some are still at different stages of clinical 
evaluations.4,9,24  
Subsequently, liposomal research has been pioneered to include targeting moieties which are 
responsible for cell targeting, as well as higher drug accumulation at the desired site.3  Targeting 
agents, such as monoclonal antibodies, growth factors, glycoproteins, and ligands, can be 
attached either to the bilayer surface or distal ends of the PEG-lipid chains.  However, studies 
have shown that the targeting ligands at the end of PEG chains are more preferred.3,9  Recently, 
liposome technology was upgraded to stimuli-responsive systems which involve programmed 
delivery of liposomal contents via specific stimulus at the targeted site.3  The stimulus can be 
either exogenous (radiation, temperature) or endogenous (pH and enzyme).25  Construction of 
these formulations, typically achieved by designing a lipid bilayer with a triggerable 
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functionality or subunit that is responsible for destabilizing the bilayer, upon induction of the 
appropriate stimulus.11,12,25  So far, several numbers of stimuli-responsive liposomes have been 
engineered using radiation,26,27 enzymes,28,29 pH,30 metal ions31 and heat32,33 as stimuli.  
However, the use of endogenous stimuli are highly favorable because it offers “local control over 
payload delivery”.12  On that note, the use of certain over-expressed enzymes at pathological 
sites provides an opportunity for their use as an internal stimulus, thereby resulting in 
programmed site-specific drug delivery.11  Consequently, several liposomal formulations based 
on tumor selective enzymes, such as secretory phospholipase A2 (sPAL2)34 and matrix 
metalloproteinases (MMP–2 and MMP–9)35-37 have been studied.  
1.3 Rate Enhancement in Trimethyl-lock induced lactonization  
In 1959, Cohen and Schmir observed that the ortho-hydroxyhydrocinnamic acid 
compounds undergo facile imtramolecular cyclization in order to form their corresponding 
lactone derivatives.38  After this initial observation, researchers investigated the reaction 
extensively.  Cohen and Milstien conducted their preliminary study with a series of ortho-
hydroxyhydrocinnamic acids (1) containing both electron donating and electron withdrawing 





                                  X = OH, OCH3, C2H6, H, F, Cl, NO2, N(CH3)3+ 




In weakly acidic conditions, the reaction proceeded at medium rates, while it was 
catalyzed by both acidic and basic buffer components.  Catalysis was concurrent and 
independent, but not concerted.  From the kinetic results (from the linear free energy relationship 
data), researchers concluded that the reaction proceeds through a tetrahedral intermediate, 
wherein breakage of the tetrahedral intermediate is key to the rate limiting step.39,40 
Subsequent studies that involved a variety of structurally distinct ortho-
hydroxyhydrocinnamic acid compounds also confirmed the breakage of the tetrahedral 
intermediate as the rate determining step, and it was found to follow pseudo-first-order 
kinetics.40-43  Moreover, it was observed that introduction of methyl substitution on 3, 3′, 4′, and 
6′ positions had a significant effect on rate of lactonization, and were 1010-1011 times as fast as 
unsubstituted hydroxyhydrocinnamic acid under buffer catalysis.  For example, the reaction was 
found to have a half life of 6 s at pH 7 and temperature 30 °C.40,41,43,44  Additionally, rate data 
revealed that the tetrahedral intermediate is more sensitive to acid catalysis compared to base 
catalysis in the rate-determining step.41  This finding reveals the significance of the surrounding 
methyl groups, and in an attempt to explain the outcome, the concept of the “trimethyl-lock” or 
“stereopopulation control” has been developed.41,44  The trimethyl-lock effect arises from the 
unique interlocking arrangement of the gem-dimethyls and single methyl at 3 and 6′ 
positions(Scheme 1), and the explanation of the outcomes states that “the effect is attributed to a 
unique interlocking of methyl groups, which produces a severe conformational restriction of the 
side chain and ground-sate geometry highly favorable to formation of the transition state”.41  The 
results, as well as Cohen’s explanation, attained much interest, and many experimental 
(crystallographic and spectroscopic) and theoretical works were conducted to verify the rate 
enhancement.40,45-47  As a result, different explanations emerged, and from empirical force-field 
10 
	  
model calculations, it was argued that conventional steric strain relief is the dominant factor 
compared to stereopopulation control.11,47  
In addition, later work by Caswell and Schmir determined that the lactonization rates for 
these compounds were overestimated, 42 and thus, Cohen later on revised the value 1010-1011  as 
105.48  These values were compatible with rate values obtained from other trimethyl-locked 
related systems.48  Furthermore, kinetic studies on ortho-hydroxyhydrocinnamic acids possessing 
different substituents at the 6′ position have shown different rates of lactonization, indicating the 
importance of the size of the substituent for accelerated lactonization;49 thus it was concluded 
that steric strain relief is the major factor for trimethyl-lock induced lactonization. 
1.3.1 Applications of the Trimethyl-lock System  
After those pioneering observations (above), research has progressed toward the 
utilization of trimethyl-lock induced lactonization to other relevant applications.  Because the 
parent trimethyl-lock ortho-hydroxyhydrocinnamic acid is highly reactive, scientists modified 
the parent structure for further applications.  As a result, a variety of trimethyl-lock quinone 
propionic acids and their amide or ester derivatives have been developed.50-53  Upon reduction, 
the quinone is converted to the hydroquinone which then undergoes intramolecular lactonization 
to release alcohols or amines to the medium (Scheme 2).  So far, several trimethyl-lock quinone 
propionic acid-based systems have been introduced, but only a few selected systems are 
discussed here.  
 
 
X = OR, NR1R2 












































The development of new prodrug systems that can utilize the tumor microenvironment as 
a stimulus for release of an active form of a given drug is a topic of current interest.54  One 
possible methodology to accomplish this target is the derivatization of the drug with a trimethyl-
lock quinone proionic acid to form their ester or amide derivatives.  For example with cancer, 
this arrangement is highly beneficial because it increases the drug’s (cytotoxic agent’s) stability 
thereby decreasing its toxic side effects before reaching the tumor site.54  When it enters the site, 
the tumor hypoxic environment facilitates prodrug bioreductive activation through the presence 
of overexpressed reductase enzymes, and as a result intramolecular lactonization of thrimethyl-
lock quinone propionic amide occurs to release the cytotoxic agent to the surroundings.54  
Chikhale et al. followed this approach to selectively deliver the methyl ester of melphalan and 
acivicin to tumor site.  In addition, they investigated the stability and efficiency of drug release 
via structural modification of the parent quinone ring.50-52  So far, several prodrug systems have 
been reported for chemotherapy based on this methodology.54-56  
  In 1999, Wang and coworkers developed a redox-sensitive resin linker, based on a 
trimethyl-lock quinone propionic acid, for solid phase synthesis of C-terminally modified 
peptides where, the linker was disintegrated  through mild reduction conditions.57  Described in 
another paper published by Lin’s group, is a trimethyl-lock quinone latent flurophore system 
based on rhodamine 110 for possible cancer cell imaging.  The system was targeted for DT 
Diaphorase, an oxidoreductase that is overexpressed in certain cancer cells and is able to 
generate or release fluorescently active rhodamine 110 dye.58  Silvers and McCarley went on to 
greatly improve latent fluorophores for cancer diagnosticis by developing a single-trigger probe 
based on a trimethyl-lock quinone propionic acid-rhodamine.59   
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Mrksich and Hodneland created a novel dynamic electroactive monolayer system on gold 
surfaces capable of selectively liberating immobilized ligands under electro-chemical control.  
The ligand, biotin, is attached to the alkanethiolate through a quinone propionic ester.  
Application of a reducing electrochemical potential to the gold surface causes quinone reduction, 
and after lactonization, biotin is released. This new class of self-assembled monolayer system is 
important for development of tailored structures for both mechanistic and experimental studies in 
cell biology.60   
In 2005, the McCarley research group initiated use of trimethyl-lock quinone propionic 
acids for stimuli-sensitive systems.  As a first step, they established the new redox-sensitive 
symmetric poly(propylene imine), PPI, dendrimer system, containing trimethyl-lock quinone 
propionic acids as peripheral groups.61,62  Secondly, in 2007, they developed redox-responsive 
aggregates by using trimethyl-lock quinone propionic acid-modified amphiphilic molecules.63  
Both systems were dissembled upon redox activation and were able to release their entrapped 
cargo in an efficient manner.  Currently, the McCarley research group is extending this concept 
to develop new liposomal formulations. 
1.4 Redox-Responsive Quinone Trimethyl-lock Liposome Delivery System  
In 2008, the McCarley research group extended the use of trimethyl-lock quinone propionic 
acids to develop a novel stimuli-responsive liposome system.12  This system, which is currently 
under its optimizing stages, utilizes dioleoylphosphatidylethanolamine (DOPE) lipids with 
trimethyl-lock quinone propionic acid attached as head groups (Q-DOPE).  Liposomes are 
targeted for human NAD(P)H:quinone oxidoreductase (hNQO1) enzyme, that is overexpressed 
in certain cancerous cells (A549, HT29).  The development of such a stimuli-sensitive liposome 
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system is highly beneficial, because it offers potential “local control over payload release” upon 
redox stimulus.8,11,12  
The overall structure of the liposome to function as a smart pharmaceutical carrier is 
permitted by the specific role played by each component of the Q-DOPE system.  The process of 
liposome destabilization is attributable to the lipid’s lamellar-to-inverted hexagonal (Lα-HII) 










                                                R1 = CH3, nPrNH, Br, H 
                                                R2, R3, Y = CH3                                           
Figure 1.1: Mechanism of Q-DOPE liposome destabilization (representation by Dr. N. H.  
       Carrier). 
 
Initial reduction of the quinone ring initiates head group removal from the lipid via 
lactonization.  Then, the exposed lipids in the bilayers of the liposomes experience inter 
liposomal electrostatic interactions, leading to apposed bilayer fusion.  This fusion induces 
destabilization in the bilayer, resulting in the Lα-HII phase transition that causes removal of 
contents to the external environment.  Owing the Lα-HII transition, the lipids rearrange to a stable 
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cone-shaped inverted miceller structure to minimize their electrostatic attraction between 
positively charged amine and the negatively charged phosphate groups (Figure 1).11  
  Recently, Nicole Carrier from the McCarley research group synthesized a family of redox-
responsive quinone-dioleoylphosphatidylethanolamine liposomes, by varying the functionality at 
the 3′ position of the quinone head group (QMe-DOPE, QBr-DOPE, QnPrNH-DOPE, QH-DOPE).  
The payload release kinetics were studied using fluorescence spectroscopy under anaerobic 
conditions.11  Following injection of chemical reducing agent (Na2S2O4), liposomes were 
destabilized, and the entrapped calcein was released at different rates (Figure 2).  Quantitatively, 
QBr-DOPE showed faster release profile while QH-DOPE revealed slower release.  The QnPrNH-
DOPE and QMe-DOPE revealed almost similar medium rate release profile.11  This observation 
points to the fact that quinone head group lactonization plays a major role in liposomal payload 
release kinetics.  Therefore, investigation of lactonization kinetics of trimethyl-lock quinones is 









Figure 1.2: Calcein release profiles (normalized) of various Q-DOPE liposomes as determined  
                   by fluorescence emission spectroscopy (λex=490 nm, λem = 515 nm).  Each trace  
                   represents the typical release behavior observed for each Q-DOPE liposome  
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SYNTHESIS AND CHARACTERIZATION OF QUINONE COMPOUNDS 
 
2.1 Syntheses 
2.1.1 Chemicals and General Methods 
All the chemicals were purchased from Sigma-Aldrich, Acros Organic, or TCI America 
and used as received.  Flash chromatography was conducted using a Biotage FlashMaster 
Personal Chromatography system with SPE ISOLUTE FLASH Silica II columns (pore size 60 
Å, diameter 40-63µm, disposable).  Reactions were followed by TLC on precoated silica plates 
(60 Å, F254, EMD Chemicals Inc) and were visualized by UV lamp (UVGL-25, 254/365 nm).  1H 
NMR spectra were recorded with either Bruker AV-Liquid-400 MHz or Bruker DPX 400MHz 
spectrometers.  ESI-mass spectra were collected using an Agilent Technologies 6210 ESI-TOF 
LC/MS instrument with 90% acetonitrile as solvent. 








   
  Scheme 2.1: Synthesis of succinimidyl ester of N-(methyl)amino quinone propionic acid. 
  
 




















Scheme 2.3: Synthesis of quinone propionic acid 4-(N-methylamino)phenol derivative. 
2.3 Experimental Details  
The compounds 1a, b, d, e, 3 and 6 were previously synthesized by members of our 
group, and purity of these were checked by 1H NMR before used.1  The References for the 
synthetic procedures are cited at the end of each procedure. 
2.3.1. Synthetic Procedures for compounds 2a-f, 4, 5 and 7 
(4). Lactone 3 was dissolved (0.690 g, 3.14 mmol) with stirring in 26 mL of glacial acetic acid.  
To this solution, Br2 (0.35 mL, 6.81mmol) in 4.2 mL of HOAc was added slowly at room 







extracted with DCM (3 × 30 mL).  The combined organic extracts were washed with water (2 × 
20 mL) and next with saturated NaHCO3 (5 × 20 mL).  Then the bicarbonate extracts were made  
acidic by adding 30% HCl (15 mL) and the resulting solution was extracted with DCM (3 × 30 
mL).  These organic extracts were washed with water (50 mL), dried with MgSO4, and 
concentrated to give a yellow oil (0.88 g, 89%).  The crude oil was directly used for amination 
reaction without further purification.  1H NMR (CDCl3) δ 1.46 (s, 6H, geminal CH3), 2.18 and 
2.20 (s, 3H, CH3), 3.04 (s, 2H, CH2).1,2 
(5). Bromo acid 4 (0.580 g, 1.85 mmol) was dissolved in 16 mL of MeOH and 40% aqueous 
methylamine (225µL, 6.42 mmol) was added with stirring at room temperature.  The system was 
tightly stoppered, and the reaction was continued for 48 hours.  Next the mixture was diluted to 
250 mL with water.  After dilution, 20 mL of 5% HCl solution was added.  The resulting 
solution was extracted with EtOAc (3 × 70 mL), and the combined organic extracts were washed 
with 140 mL of saturated NaCl solution.  The solution was dried over MgSO4, and solvent was 
removed with the use of a rotary evaporator to give a red-purple oil.  The crude oil was purified 
by silica column using hexanes/ethylacetate/acetic acid (14:6:1) as eluent.  Concentration of the 
major red fraction afforded a red-purple oil, which was taken up in 50 mL of DCM and washed 
with water (2 × 40 mL) to remove the acetic acid.  Next the DCM layer was dried over MgSO4 
and solvent was removed with a rotary evaporator to give a red-purple oil (0.26 g, 53%).  1H 
NMR (CDCl3) δ 1.45 (s, 6H, gem CH3), 2.07 (s, 3H, quinone CH3), 2.20 (s, 3H, quinone CH3), 
2.99 (s, 2H, CH2), 3.11 (s, 3H, N-methyl CH3), 5.15 (broad peak, N-methyl H).  HRMS (ESI) 
m/z [M+H]+, calculated = 266.1392, observed = 266.1387; 1.88 ppm error.1,2 
(1c). Dicyclohexylcarbodiimide (0.095g, 0.436 mmol) was added to a solution of quinone 




mL of dry THF at 0 °C.  The mixture was continuously stirred for 24 hours under argon.  The 
remained solution was filtered to remove the dicyclohexylurea, evaporated using a rotary 
evaporator, and then treated with 10 mL of EtOAc.  The corresponded solution was filtered 
again.  This sequence was repeated for four times to remove the unreacted dicyclohexylurea.  
The solvent was removed with rotary evaporator, and the red crude material was purified on 
silica column using dichloromethane/ethylacetate (14:1) as eluent to give 55 mg (39%) of red 
solid.  *The purified product was contaminated but used for the synthesis of 2c.  1H NMR 
(CDCl3) δ 1.57 (s, 6H, geminal CH3), 2.07 (s, 3H, CH3), 2.22 (s, 3H, CH3), 2.72 (s, 4H, CH2), 
2.80 (s, 2H, CH2), 3.25 (s, 3H, CH3), 5.30 (broad peak, N-methyl H).  HRMS (ESI) m/z [M+H]+, 
calculated = 363. 1556, observed = 363.1592; 9.91 ppm error.1,2  
 (2a). In a typical procedure, ethanolamine (0.044 g, 0.72 mmol) was added dropwise to a 
solution of 1a (0.111 g, 0.320 mmol) in dichloromethane (12 mL).  The mixture was stirred for 
15 hours at room temperature under inert environment.  The reaction mixture was diluted with 
DCM and filtered to remove the white solid that appeared in the middle of the reaction.  Solvent 
was evaporated using a rotary evaporator and the crude mixture was purified on silica column 
using ethylacetate/dichloromethane (1:1) as eluent.  Finally solvent was evaporated to give a 68 
mg of yellow solid (72%).  1H NMR ( CDCl3) δ 1.45 (s, 6H, gem CH3), 1.96 (s, 3H, quinone 
CH3), 1.98 (s, 3H, quinone CH3), 2.14 (s, 3H, quinone CH3), 2.86 (s, 2H, CH2), 3.35(t, 2H, 
ethanolamine-CH2), 3.65 (t, 2H, ethanolamine-CH2), 5.81 (broad peak, ethanolamine H).  HRMS 
(ESI) m/z [M+H]+, calculated = 294.1705, observed = 294.1568; 46.57 ppm error.3  
(2b) Starting material 1b was used to synthesize 2b and it was synthesized and purified 
following the same steps utilized in procedure 2a.  Yield 70%.  1H NMR ( CDCl3) δ 1.47 (s, 6H, 




3.67 (t, 2H, ethanolamine-CH2), 5.84 (broad peak, ethanolamine H).  HRMS (ESI) m/z [M+H]+, 
calculated = 358.0654, observed = 358.0650; 1.12 ppm error. 3 
(2c). Starting material 1c was used to synthesize 2c and it was synthesized and purified following 
the same steps utilized in procedure 2a.  Yield 55%.  1H NMR ( CDCl3) δ 1.44 (s, 6H, gem 
CH3), 2.05 (s, 3H, quinone CH3), 2.18 (s, 3H, quinone CH3), 2.80 (s, 2H, CH2), 3.11 (s, 3H, N-
methyl CH3), 3.36 (t, 2H, ethanolamine-CH2), 3.69 (t, 2H, ethanolamine-CH2).  HRMS (ESI) m/z 
[M+Na]+, calculated = 331.1634, observed = 331.1640; 1.81 ppm error.3  
(2d). Starting material 1d was used to synthesize 2d and it was synthesized and purified 
following the same steps utilized in procedure 2a.  Yield 64%.  1H NMR (CDCl3) δ 0.97 (t, 3H, 
propyl CH3), 1.44 (s, 6H, gem CH3), 1.58 (m, 2H, CH2CH2CH3), 2.01 (s, 3H, quinone CH3), 2.17 
(s, 3H, quinone CH3), 2.79 (s, 2H, CH2), 3.33–3.39 (m, 2H, NCH2CH2CH3+2H, NCH2CH2OH), 
3.64 (t, 2H, ethanolamine-CH2 ), 5.79 (broad peak, ethanolamine H), 5.81 (broad peak, N-propyl 
H).  HRMS (ESI) m/z [M+H]+, calculated = 337.2127, observed = 337.2219; 27.28 ppm error. 3 
(2e). Starting material 1e was used to synthesize 2e and it was synthesized and purified following 
the same steps utilized in procedure 2a.  Yield 43%.  1H NMR (CDCl3) δ 1.46 (s, 6H, gem CH3), 
2.00 (s, 3H, quinone CH3), 2.18 (s, 3H, quinone CH3), 2.88 (s, 2H, CH2), 3.34 (t, 2H, 
ethanolamine-CH2), 3.66 (t, 2H, ethanolamine-CH2), 6.51 (s, H, quinone H) 5.81 (broad peak, 
ethanolamine H).  HRMS (ESI) m/z [M+H]+, calculated = 280.1549, observed = 280.1551; 0.71 
ppm error. 3 
(2f). Methylethanolamine (0.049 g, 0.66 mmol) was added dropwise to a solution of 1f (101.70 
mg, 0.293 mmol) in dichloromethane (12 mL).  The mixture was stirred for 15 hours at room 
temperature under inert conditions.  The reaction mixture was diluted with DCM and filtered.  




column using ethylacetate/dichloromethane (2:1) as eluent.  Finally solvent was evaporated to 
give a 53 mg of yellow solid (59%).  1H NMR (CDCl3) δ 1.45 (s, 6H, gem CH3), 1.92 (s, 3H, 
quinone CH3), 1.94 (s, 3H, quinone CH3), 2.14 (s, 3H, quinone CH3), 2.86 (s, 2H, CH2), 3.02 and 
3.06 (2×s, 3H, N-methylethanolamine CH3), 2.70, 3.46, 3.70, 3.81 (N-methylethanolamine CH2).  
HRMS (ESI) m/z [M+H]+, calculated = 308.1862, observed = 308.1871; 2.92 ppm error.3  
(7). 4-(methylamino)phenol (0.109 g, 0.885 mmol) was dissolved with stirring in 10 mL of 
DMF.  To this solution, quinone acid 6 (0.207 mg, 0.827 mmol) in 5 mL of DMF was added at  
0°C.  HATU (0.308 mg, 0.812 mmol) and DIEA (161µL, 0.975 mmol) were added to the 
reaction mixture sequentially, and the mixture was gradually warmed to room temperature 
overnight.  Next, the solution was extracted with EtOAc (3 × 20 mL) and combined organic 
extracts were washed with saturated NaCl (2 × 20 mL) solution.  The solution was dried over 
MgSO4 and solvent was removed with the use of rotary evaporator to give a yellow solid.  The 
crude solid was purified by silica gel column using hexanes/ethylacetate (2:5) as eluent.  Solvent 
was evaporated to yield 238 mg (81%) of yellow solid.  
1H NMR (CDCl3) δ 1.31 (s, 6H, gem CH3), 1.96 (s, 3H, quinone CH3), 2.00 (s, 3H, quinone 
CH3), 2.17 (s, 3H, quinone CH3), 2.75 (s, 2H, CH2), 3.12 (s, 3H, N-methyl CH3), 6.87–7.08 (d, 
4H, benzene H,).  HRMS (ESI) m/z [M+H]+, calculated = 356.1862, observed = 356.1858; 1.12 
ppm error.  
2.4 Summary 
A series of seven different simple quinone propionic acid amide derivatives (2a–f and 7) 
were synthesized by varying the amide structure or substituents on the parent quinone ring.  All 




1H NMR and ESI-MS techniques for subsequent reduction and lactonization kinetic studies (see 
chapter 3).  
2.5 Spectral Data 
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KINETIC STUDIES ON LACTONIZATION OF QUINONE PROPIONIC ACID AMIDE 
DERIVATIVES BY 1H NMR FOR DEVELOPMENT OF REDOX-ACTIVE LIPOSOMES 
 
3.1 Introduction 
Liposomes are extremely versatile and malleable nanocarriers that attract great interest in 
drug delivery.1  At present, the development of stimuli-responsive liposomal formulations that 
utilize endogenous triggers for cancer therapy is vast of interest.2-5  Such systems have the ability 
to improve tumor selectivity and the activity of the anticancer agent compared to free drug, and 
hence other reduced harmful side effects.2,6  However, the effectiveness of liposomal drugs not 
only depends on the properties of the encapsulated drug, but also on the pharmacokinetics, rate 
of drug release, and bio-distribution of the liposome carrier.  Therefore, optimization of these 
carrier properties, especially the rate of drug release, is vital for chemotherapy.1,7,8 
Liposomes that exhibit longer circulation life time, as well as therapeutically optimized drug 
release rates, are highly beneficial for in vivo therapeutic applications.1  The relationship between 
circulation life time and antitumor activity was found to be directly proportional for various 
tumor models.  In other words, extended circulation life times have revealed higher antitumor 
activity.9,10  The same trend was observed with respect to rate of drug release from liposomes as 
anticancer agents which have shown greater stability and activity with prolonged exposure to 
cancerous cells.1  Johnston and coworkers have demonstrated that vincristine, the cell cycle 
specific agent, has caused extensive antitumor activity with slower release rates for L1210, P388 
(murine leukemia) and A431 (human squamous cell carcinoma) tumor models.6  In addition, 
Drummond et al. have revealed a similar relationship against HT-29 (human colon carcinoma) 
and BT-474 (human breast carcinoma) cells with liposomal formulations of vinorelbine and 
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irinotecan, respectively. 1,11  Thus, it is important to optimize the drug releasing rate of liposomes 
in order to maximize the drug bioavailability, and hence, higher antitumor activity.  
Inspired by the findings of redox-induced facile lactonization of trimethyl-lock quinones by 
Carpino and others,12-14 the McCarley research group developed a new liposome system, where 
lipid (DOPE) head groups are capped with trimethyl-lock quinone propionic acid group.15  Initial 
studies confirmed high stability, as well as stimulated payload release behavior, leading to the 
current work of optimization.  Upon induction of a redox-stimulus, the quinone head group 
undergoes lactonization that leads to its cleavage from the DOPE lipid.  Once the head group is 
released, naked lipid goes through a lamellar to inverted micelle hexagonal (Lα to HII) phase 
transition, leading to release of the encapsulated contents.15  Thus far, the McCarley research 
group has formulated four different liposome systems by varying the substituent at the 3′ position 
of the trimethyl-lock quinone propionic acid system (QH-DOPE, QMe-DOPE, QBr -DOPE, and 
QnPr-DOPE).  Payload release studies of calcein entrapped in liposomes, using fluorescence 
spectroscopy, demonstrated the different liposomes to have unique release profiles.8  The results 
indicate that the quinone head group plays an important role during the destabilization process, 
especially in the process of lactonization.  Therefore, it is essential to identify the mechanism and 
kinetics of lactonization, such that liposome rupture can be modified to match the drug efficacy 
profiles and thereby improve therapeutic impact.  
After the discovery of the trimethyl-lock ortho-hydroxyhydrocinnamic acid undergoes facile 
lactonization, research has progressed to identify its mechanism and rates of reaction.16  Cohen 
and several other research groups extensively studied the lactonization process of ortho-
hydroxyhydrocinnamic acids experimentally and figured out the mechanism as follows.  The 
phenolic moiety of the ortho-hydroxyhydrocinnamic acid undergoes nucleophilic attack at the 
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propionic acid carbonyl to yield a tetrahedral intermediate in an equilibrium process.  Then the 
intermediate proceeds via collapse to form the lactone via the slower rate determining step.16-20  





Scheme 3.1: General mechanism of trimethyl-lock quinone lactonization. 
 Currently, we are developing two major types of liposome formulations using the following 
parent lipid structures (Figure 3.2).  Because lactonization plays a major role in the process of 
liposome destabilization, it is critical to find out the rate of cyclization of these structures upon 
reduction, so as to fully understand liposome contents release.  In order to achieve this target, 
model compounds of different trimethyl-lock quinone propionic acid amide derivatives were 
synthesized by varying the amide structure (R1, R2) and the functional group at the 3′ position 
(R3, Figure3.1: quinone-ethanolamine (R3 = CH3, Br, NPr, H, NMe, R2 =H, R1 = CH2CH2OH; Q-
ETA), quinone-methylethanolamine (R3 = CH3, R2 = CH3, R1= CH2CH2OH; Q-MeETA), 
quinone-methylaminophenol (R3 = CH3, R2 =CH3 =R1 =C6H5OH; Q-NMeBnOH)).  Synthesized 
derivatives mimic the parent lipid structure to a greater extent and follow the same mechanism 











Figure 3.1: Amide derivative of trimethyl-lock quinone propionic acid. 
Nuclear magnetic resonance (NMR) spectroscopy is a powerful tool to investigate 
compound behavior with respect to different perturbations.12,21  Therefore, 1H NMR experiments 
were carried out to investigate the lactonization behavior of the synthesized derivatives.  The 
results described herein explain the effect of varying the 3′ quinone functionality, amide structure 
(R1, R2) as well as reaction conditions including temperature, solvent, and buffer toward the rate 










Figure 3.2: Parent lipid structures a) Q-DOPE b) Q-AQM-DOPE used for liposome formation. 
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3.2 Experimental Section 
 3.2.1 Materials 
Deuterated solvents (D2O, d6-DMSO 98%), potassium dideuterium phosphate (KD2PO4), 
dipotassium deuterium phosphate (K2DPO4), potassium chloride (KCl), deuterated sodium 
hydroxide (NaOD), sodium hydroxide pellets (NaOH), methanol (MeOH), and sodium dithionite 
(Na2S2O4) were purchased from Sigma Aldrich.  Except sodium dithionite, all the other 
chemicals were used as received.  Sodium dithionite was purified before use (Section 3.2.2).  
Previously synthesized ferrocene salt (C18H20F6FeNP, Figure 3.3) was used as an internal 






Figure 3.3: Ferrocene salt, internal standard used for 1H NMR experiments. 
3.2.2 Sodium Dithionite (Na2S2O4) Purification 
Commercially available sodium dithionite (6 g) was dissolved in 40 mL of degassed 0.1N 
NaOH solution under inert conditions.  To this solution, 45 mL of degassed MeOH/ 0.1N NaOH 
(4:1) solution was slowly added through a syringe until crystals form from the solution.  Once 
crystals appeared, the solution was drained and this sequence was repeated for a total of three 
times to gain purified dithionite crystals.  Purified wet dithionite crystals were then vacuum dried 




3.2.3 Deuterated Buffer Preparation  
Potassium dideuterium phosphate (23.74 mg, 0.0333M), dipotassium deuterium 
phosphate (59.12 mg, 0.0666M), and potassium chloride (38.24 mg, 0.1 M) were dissolved in 5 
mL of D2O solution while adjusting to required pD (7.21 or 7.41) using deuterated sodium 
hydroxide to gain a 0.1 M phosphate buffer solution. 
3.2.4 Instrumentation 
3.2.4.1 Nuclear Magnetic Resonance Spectroscopy (NMR) 
Kinetic experiments were conducted using either a Bruker AV Liquid 400 MHz or 
Bruker DPX 400MHz spectrometer. After addition of chemical reducing agent (Na2S2O4), 
successive spectra were collected at 1 min 33 second or 2 min 29 second intervals, and each 
spectrum was set to acquire 16 or 32 scans with pre-scan delay.  The spectra were normalized 
with respect to the three methyls (δ 2.85 ppm) of the ferrocene internal standard.  The change in 
integrals of gemdimethyls was used as index to evaluate the kinetics.23 
3.2.5 General Procedure for Sample Preparation  
3.2.5.1 D2O as Solvent 
An internal standard solution was prepared by dissolving ferrocene salt in Figure 3.3 
(0.02–0.03 g) in D2O (3 mL).  The quinone-amide compound (0–3 mg) was dissolved in this 
same internal standard solution (700 µL), and the initial 1H NMR spectrum was recorded.  A 
similar amount of the quinone-amide (0–3 mg) was dissolved in 500 µL of the internal standard 
solution.  To this solution, an excess of sodium dithionite (5:1, S2O42–:quinone-amide) in 200 µL 
of internal standard was added, and successive 1H NMR spectra were recorded.  All the NMR 




3.2.5.2 DMSO-D2O as Solvent 
Ferrocene salt in Figure 3.3 (2–3 mg) and the quinone-amide compound (0–4 mg) were 
dissolved in a 5:2 (v/v) mixture of DMSO and D2O (700µL) and the initial 1H NMR spectrum 
was recorded.  A similar amount of ferrocene salt in Figure 3.3 (2–3 mg) and quinone-amide 
compound (0–4 mg) were dissolved in 500 µL of DMSO, and to this solution, an excess of 
sodium dithionite (5:1, S2O42-:quinone-amide) in 200 µL of D2O was added.  1H NMR spectra 
were recorded successively.  All the NMR solutions were degassed before spectral acquisition.  
3.3 Results and Discussion 
3.3.1 Lactonization Behavior of Q-ETA Derivatives 
3.3.1.1 Effect of Functional Group 
To investigate the effect of quinone functionality at the 3′ position on the quinone on 
lactonization, five different quinone-ethanolamine (Q-ETA) derivatives were synthesized (QMe-
ETA, QBr-ETA, QNMe-ETA, QH-ETA, QNPr-ETA) and were subjected to 1H NMR experiments 
according to the procedure described in Section 3.2.5.1 in D2O medium.  Compounds showed 
different lactonization profiles after reduction, and the behavior of each derivative will be 
discussed in the following paragraphs.  
In Figure 3.4 is shown the reduction and lactonization behavior of QMe-ETA upon 
addition of sodium dithionite (reducing agent).  1H resonances of all the peaks were shifted 
downfield with respect to the initial spectrum (Figure 3.4 A) by 0.25 ppm and that spectrum was 
attributable to the corresponding tetrahedral intermediate (Figure 3.4 B).  This outcome was 
expected, due to previous UV spectroscopic studies confirming the quinone is essentially 
instantly (100 ms) reduced to hydroquinone, and its rapid transformation to the tetrahedral 
intermediate24.  In the successive spectra, the intensity of peaks indicated as a′, b′, c′, d′, e′ and 
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g′ decreased, while that of the peak indicated as h′ was increased with time.  The intensity of the 
peak denoted as f′ remained constant.  The changed signals, a′, b′, c′, d′, and e′ are associated 
with the time-dependent lactone formation, whereas remaining signals, f′ and h′ are associated 
with release of ethanolamine to the medium.  The lactone precipitated from solution, resulting in 
a decrease of the corresponding signals in the spectrum.  The process was completed 
approximately after 170 minutes (Figure 3.4 F) and was verified by the respective control 
experiment.  The Figure 3.5 is shown the spectra for an authentic sample of QMe-lactone with 
ferrocene (top) and the lactonized product after completion of the reaction (bottom).  Because 












Figure 3.4: Time-dependent QMe-ETA (3.8 × 10–3 M) lactonization in pure D2O by 1H NMR.   
                   The signals at δ 2.85 ppm and 4.20–4.50 ppm are associated with the internal  






























Figure 3.5: Confirmation of QMe-lactone (4.8 × 10–3 M) precipitation in pure D2O by 1H NMR.  
                  The signals at δ 2.85 ppm and 4.20–4.50 ppm are associated with the internal  
                  standard. 
 
In order to evaluate the kinetics of the process, integration of the gemdimethyl signal at 1.46 
ppm of successive spectra were collected, as its intensity is directly proportional to the remaining 
tetrahedral intermediate concentration [QMe-ETATet] at any given time.  The [QMe-ETATet] with 
respect to time was calculated using respective integrals and initial QMe-ETA concentration.  The 
plot of ln ([QMe-ETATet]t=t / [QMe-ETATet]t=0]) versus time showed linear decay (Figure 3.6) 
where reaction followed the integrated rate law of first-order kinetics and can be explained by 
following mathematical Equations 3.1 and 3.2.25,26  
                                                [QMe-ETATet]t=t  = [QMe-ETATet]t=0 e-kt .                  Equation 3.1 
           
                                           ln ([QMe-ETATet]t=t / [QMe-ETATet]t=0]) = – kt               Equation 3.2 
 
 The rate constant (k) of the lactonization process was obtained as k = 0.023 min-1 and 
half life of the reaction was calculated from Equation 3.325,26 as t ½ = 30 minutes. 







Reduction and lactonization of QBr-ETA (Figure 3.7) was rapid, and the reaction was 
complete within 5 minutes.  Bromo-lactone was precipitated from the solution, while 
ethanolamine was released to the medium.  This behavior was mainly due to the inductive 
electron withdrawing nature of the bromine functionality which facilitates faster reduction 
followed by more rapid lactonization.  Using 1% remaining reactant and t99% = 5 min, k is 
estimated to be ≥ 0.9 min–1.  Further studies on QNMe-ETA and QNPr-ETA derivatives (Figure 3.8 
and 3.9) have exhibited almost same reduction and lactonizaton profile as QBr-ETA.  The 
processes were completed within 3 minutes possibly due to the internal base catalysis behavior 
of nitrogen atom of NMe and NPr groups.  Using 1% remaining reactant and t99% = 3 min, k is 
estimated to be ≥ 1.5 min–1.  However, the resulting lactones were soluble in the D2O medium 











Figure 3.6: Kinetic evaluations of QMe-ETA lactonization in pure D2O medium. 
 










Parameter Value   Error
------------------------------------------------------------
B         -0.02267  2.65012E-4
------------------------------------------------------------
R    SD       N     P
------------------------------------------------------------
-0.99574  0.12127     25  <0.0001
------------------------------------------------------------




























Figure 3.7: Time-dependent QBr-ETA (3.16 × 10–3 M) lactonization in pure D2O by 1H NMR.   












Figure 3.8: Time-dependent QNMe-ETA (3.80 × 10–3 M) lactonization in pure D2O by 1H NMR.   
























































 Figure 3.9: Time-dependent QNPr-ETA (3.02 × 10–3 M) lactonization in pure D2O by 1H NMR.   
                    The signals at δ 3.00 ppm and 4.30–4.60 ppm associated with the internal standard.   
                    The signals denoted as asterisks indicate the residual solvents that remain from the  
                    purification. 
On the contrary, QH-ETA compound has shown a complicated spectrum in D2O medium, 
where the peaks corresponding to methyls were split even before adding the reducing agent 
(Figure 3.10 A).  This observation might be due to the formation of one or more degradation 
products, such as spirolactams in aqueous condition (Scheme 3.2).27  Formation of spirolactam 
has been an extensively studied concept, and is more prominent in base-catalyzed soft reaction 
conditions.27-29  Base mediated (D2O) deprotonation of the amide nitrogen facilitates the negative 
charge formation on nitrogen, resulting a highly reactive nucleophilic species that can attack the 
quinone ring to form several products.29  However, the formation of product 5 (Scheme 3.2) is 
thermodynamically less favorable, but it might be kinetically possible owing to the release of 
steric strain involved in the trimethyl lock system.27  Therefore, more research is required to 
































Scheme 3.2: Possible degradation routes of QH-ETA in aqueous condition in the absence of a 













Figure 3.10: Time-dependent QH-ETA (4.7 × 10–3 M) lactonization in pure D2O by 1H NMR.     
                     The signals at δ 2.85 ppm and 4.20–4.50 ppm associated with the internal standard.   
                     Asterisk (*) and (x) represent the increasing and decreasing signals respectively. 
 
Upon introduction of the reducing agent, peaks were shifted downfield, and the spectrum 










spirolactam product (Figure 3.10 B).  Peaks denoted by an asterisk (*) increased, while peaks 
symbolized as (x) were decreased with time.  The others remained constant throughout the 
experimental period.  However, no detectable precipitation of lactone occurred for 6 hours 
(Figure 3.10 C-E), revealing the much slower lactonization process in D2O medium.  
Furthermore, the spectrum of pure QH-ETA in CDCl3 was recorded to assess the possibility of 
spirolactam formation under organic conditions.  The spectrum did not show any splitting as in 
the previous, thus confirming that degradation does not take place in an organic medium (Figure 
3.11).  The same trend was observed with the QH-COOH system, pointing out that the H 














Figure 3.11: Spectral comparison of QH-ETA in (a) CDCl3 and (b) D2O medium.  Asterisk (*)  
                    at 4.65ppm in spectrum (b) represents the noise peak. 
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Figure 3.12: Spectral comparison of QH-COOH in (a) CDCl3 and (b) D2O medium. 
3.3.1.2 Effect of Organic Solvents 
 As a majority of bulky quinone propionic amide derivatives do not dissolve in aqueous 
medium, it is important to understand how the presence of organic solvents affect their rate of 
reduction and lactonization.  Thus, as an initial attempt, lactonization studies were conducted 
with QMe-ETA in a mixture of DMSO:D2O (5:2) in order to compare the nature of the 
lactonization process with respect to aqueous conditions.   
The rate of reduction was as fast as previous studies (compare Figure 3.13 A and B to 
Figure 3.4 A and B), but the cyclization was slower compared to the study in pure D2O medium 
indicating that the tetrahedral intermediate is somewhat stable in organic medium (compare 
Figure 3.13 C through D to Figure 3.4 C through F).  However, dramatic concentration reduction 












Figure 3.13: Time-dependent QMe-ETA lactonization in a 5:2 mixture of DMSO:D2O by 1H  














Figure 3.14: Time-dependent QMe-ETA (1.7 × 10–2 M) lactonization in a 5:2 mixture of DMSO: 
                     D2O by 1H NMR in the presence of internal standard.  Both (*) & (x) denote the  
                     impurities from medium.  
 
















the salt precipitation from the medium leading to lower quinone to hydroquinone conversion. 
Both lactone and ethanolamine were soluble in the reaction medium, and the process was 
complete after approximately 17 hours (Figure 3.14 A-E).  The rate constant (k) and half life 
(t1/2) were found as 0.0026 min-1 and 2.7 × 102 minutes respectively (Figure 3.15).  Lactonization 
was 9 times slower compared to the study in D2O medium, and these findings are comparable 
with previous rate data that were obtained via cyclic voltammetry (CV)30 and UV-visible 











Figure 3.15: Kinetic evaluations of QMe-ETA lactonization in a 5:2 mixture of DMSO:D2O.  
3.3.1.3 Effect of Temperature 
Because our main goal is to use our liposome system under biological conditions, it is 
important to investigate how the temperature affects the rate of lactonization.  Therefore, 
temperature studies of QMe-ETA were performed at 10 °C, 25 °C and 35 °C in D2O medium 
(Table 3.1).  At 25 °C, the lactonization process was complete within 170 minutes.  In theory, for 










B         -0.0026 9.03338E-5
------------------------------------------------------------
R    SD    N P
------------------------------------------------------------
-0.99188 0.24881   25 <0.0001




















a given activated process, the rate of the reaction will increase with increasing temperature.26  As 
anticipated at 35 °C, the reaction reached completion within 90 minutes, due to the increased rate 
of lactonization.  Lowering the temperature of the system to 10 °C caused reaction to be 
incomplete even after 500 minutes.  Raising the temperature from 25 °C to 35 °C accelerated the 
reaction rate by two fold, whereas lowering the temperature from 25 °C to 10 °C retarded the 
process roughly by four times.  The rate constant (k) and half life (t1/2) values are summarized in 
(Table 3.1), and the associated kinetic plots are presented in Figure 3.16.  Furthermore, the 
activation energy for QMe-ETA lactonization in D2O was calculated using the rate values, and it 
was found as 59.1 kJmol-1.   
Table 3.1: Kinetic results for QMe-ETA lactonization in D2O medium at different temperatures.   
                Only one replicate obtained in each case. 
                    
 
3.3.1.4 Effect of Buffer Conditions 
In regards to liposome opening under physiological conditions, another avenue of study 
that of lactonization kinetics under buffered conditions.  In a preliminary study by Cohen and 
Milstein, a faster intramolecular cyclization of trimethyl-lock system was observed under both 
acidic and basic buffered conditions.  The catalysis was concurrent, but not concerted.16,17  
Amsberry et al. also observed the same trend under phosphate buffered conditions for model 
trimethyl-lock hydroxy amides.31  Therefore, to probe this effect further, lactonization studies of 
QMe-ETA were conducted in 0.1 M deuterated phosphate buffer medium at 25 °C.  Buffer 
solutions were prepared according the procedure described in Section 3.2.3 at a 7.20–7.45 pD 
      Temperature (°C )      Rate constant  k (min-1)       Half life  t1/2 (minutes) 
10 °C 0.0061 1.1× 102 
25 °C 0.023 30 




























Figure 3.16: Kinetic evaluations of QMe-ETA lactonization in D2O medium at a) 10 °C (3.6  
         × 10–3 M), b) 25°C (3.8 × 10–2 M), and c) 35 °C (4.3 × 10–2 M). 










B       -0.00607 2.66771E-4
------------------------------------------------------------
R     SD        N P
------------------------------------------------------------
-0.98417    0.33506    21 <0.0001
------------------------------------------------------------



























Parameter Value   Error
------------------------------------------------------------
B         -0.02267  2.65012E-4
------------------------------------------------------------
R    SD       N     P
------------------------------------------------------------
-0.99574  0.12127     25  <0.0001
------------------------------------------------------------






























B        -0.04657 0.0011
------------------------------------------------------------
R     SD       N        P
------------------------------------------------------------
-0.99351   0.20723    14      <0.0001
------------------------------------------------------------





















range, as it mimics the physiological nature to a good extent.  Both studies at pD 7.41 and 7.21 
reached completion after 35 to 45 minutes, with rate constants of 0.095 min-1, and 0.075 min-1 
respectively.  Because the rate constants were not much different, statistical analysis (t-test) was 
conducted to find out if they differ significantly.  The resulting t value confirmed the similarity 
of the rate constants at the 95 confidence level, and all results are summarized in Table 3.2 and 
related plots are presented in Figure 3.17 and 3.18.  In addition, the presence of phosphate buffer 
results in more rapid cyclization kinetics, confirms the rate of cyclization is roughly four times 
that without buffer present (Table 3.1 and 3.2). 
Table 3.2: Kinetic data for QMe-ETA lactonization in 0.1 M phosphate buffer conditions 
pD Average Rate constant (k) 
(min–1) 
Average Half life (t1/2) 
( min) 
  t-test  Values 
7.41 0.081 8.6 calculated: 0.999 
7.21 0.070 9.9 tabulated: 2.776 
 
3.3.2 Lactonization Behavior of QMe-COOH   
The lactonization behavior of QMe-COOH was studied in order to investigate the impact of amide 
presence versus free acid on the rate of lactonization.  The kinetic experiment was initially 
performed at 25 °C in D2O medium.  The free acid (QMe-COOH) cyclized rapidly compared to 
its ethanolamine analog (QMe-ETA), indicating that the amide structure has a significant impact 
on the process.  The process for QMe-COOH reached completion within 5 minutes, proving the 
acid autocatalysis ability of QMe-COOH.  Lactone precipitated from the solution, and signals for 
the lactone were not present in the 1H NMR spectrum (Figure 3.19).  A lower end estimation of k 
is roughly; 0.9 min–1, using 1% remaining reactant and t99% = 5 min.  This observation was 
supported by the preliminary research done by Cohen and coworkers that came to the same 






























Figure 3.17: Kinetic evaluation of QMe-ETA lactonization in 0.1 M, pD 7.41 phosphate buffer  
                    medium; three replicates are shown. 
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------------------------------------------------------------
R    SD     N P
------------------------------------------------------------
-0.99971  0.02688  14 <0.0001
------------------------------------------------------------

















   
   
   
   
   
   
 
Time (min)        













B        -0.095 0.00249
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-0.98563  0.18859  12 <0.0001
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Figure 3.18: Kinetic evaluation of QMe-ETA lactonization in 0.1 M, pD 7.21 phosphate buffer  
                    medium; three replicates are shown. 
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Moreover, lactonization of QMe-COOH was studied in 0.1 M phosphate buffer at pD 7.41, and 
the reaction was completed in 3 minutes as anticipated (Figure 3 20); a lower end estimation of k 
is 1.5 min–1 using 1% remaining reactant and t99% = 3 minutes. 
 3.3.3 Lactonization Behavior of Other QMe-Amide Derivatives 
To further examine how the amide structure affects the rate of lactonization, studies were 
undertaken wherein the quinone structure was held constant, while the type of amide structure 
was varied.  QMe was selected as the parent quinone structure, as it would be capable of providing 
measurable rate values.  
As an initial attempt, a kinetic study of QMe-N-methylaminophenol (QMe-NMeBnOH, 
Figure 3.21 A) was conducted to determine the impact of aromatic amide on the rate of 
lactonization.  The use of QMe-aminophenol was avoided because of its capability of forming 











Figure 3.19: Time-dependent QMe-COOH (4.3 × 10–3 M) lactonization in D2O medium by 1H  
                     NMR.  The signals at δ 3.00 ppm and 4.30–4.60 ppm associated with the internal  























Figure 3.20: Time dependent QMe-COOH (4.7 × 10–3 M) lactonization in 0.1 M phosphate buffer  
                     at pD 7.41 by 1H NMR.  The signals at δ 3.00 ppm and 4.30–4.60 ppm associated  
                     with the internal standard. 
 
The experiment was conducted in DMSO:D2O (5:2) medium due to the poor solubility of QMe-
NMeBnOH in pure D2O; the procedure described in Section 3.2.3.2 was used.  Successive 
spectra were collected for 60 minutes.  Formation of the tetrahedral intermediate was confirmed 
after addition of the reducing agent, and it was stable for more than one hour, as noted by the 
lack of spectral changes (Figures 3.21 B, C).  This confirmed the stability of the tetrahedral 
intermediate in the organic/aqueous medium.  After 12 hours, additional peaks were detected but 
the cyclization process was not complete (Figure 3.21 D).  However, observation after 69 hours 
verified completion of the process (Figure 3.21 E) where (N-methylamino)phenol and lactone 
were released to the medium, as was confirmed by the related control experiment (Figures 3.21 
E, F).  These specific observations confirmed the much slower rate of lactonization for QMe-

























Figure 3.21: Time-dependent, QMe-NMeBnOH (4.1 × 10–3 M) lactonization in a 5:2 mixture of        
         DMSO:D2O  medium by 1H NMR in the absence of internal standard.  
 
To further assess the lactonization behavior of Q-amides through fluorescence detection, 
a kinetic study of QMe-NN (Scheme 3.3) was performed in DMSO:D2O (5:2) medium.  After 
introducing sodium dithionite, some of the initial peaks shifted downfield, while most of the 
peaks remained as in the previous spectrum (Figure 3.22 A and B).  Successive spectra were 
collected for only 1 hour, and no significant changes were detected (Figure3.22 C).  After nearly 
12 hours, a decrease in intensity of the gem-dimethyl peak was observed, while some additional 
peaks appeared in the spectrum, but changes were minor (Figure 3.22 D).  However, after 24 
hours, the changes were significant, but the process was incomplete (Figure3.20 E).  The 
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lactonization was much slower, and formation of relevant NN identified by fluorescence 








Scheme 3.3: Mechanism of QMe-NN disconnection after reduction. 
From these results, it is clear that the tertiary amide structures do affect their rate of 
lactonization compared to simple analogues.  Since both QMe-NN and QMe-NMeBnOH possesses 
N-methyl group at the amide part (Figures 3.21 and 3.22), our next concern was to study the 
impact from N-methyl functionality on this process.  The QMe-methylethanolamine (QMe-
MeETA) was used to study the lactonization kinetics where it showed spectral changes in 
different solvent conditions (Figure 3.23).  The changes were significant and might be 
attributable for corresponding stereoisomers.  However, kinetics evaluation was performed in 
D2O medium due to the slower process in organic conditions which was evident from previous 
studies.  Lactone precipitated from the solution, while methylethanolamine was released to the 
medium (Figure 3.24 A-E).  Successive spectra were collected for 2 hours, and initial 
concentration changes were used for the kinetic evaluations (Figure 3.25).  The rate constant (k) 
and t1/2 were 0.013 min–1 and 53 nearly minutes, respectively, and the reaction rate constant was 





























Figure 3.22: Time-dependent QMe-NN (2.4 × 10–3 M) lactonization in a 5:2 mixture of DMSO:  
                     D2O medium by a) 1H NMR region of 0.00– 5.50 ppm  b) region of 7.50–9.75 ppm. 
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Figure 3.23: Spectral variations of QMe-MeETA in different solvents A) DMSO, B) CDCl3, and  



























Figure 3.24: Time-dependent QMe-NMeETA (1.3 × 10–3 M) lactonization in pure D2O medium     
         by 1H  NMR. The signals at δ 2.90 ppm and 4.20–4.45 ppm associated with the   











Figure 3.25: Kinetic evaluation of QMe-MeETA (1.3 × 10–3 M)  lactonization in pure D2O  
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The reduction and lactonization behavior of eight different trimethyl-lock quinone 
propionic acid derivatives were investigated by 1H NMR spectroscopy; the outcomes are 
summarized in Table 3.3.  In all amides except Br, NPr, and NMe on quinone ring, upon addition 
of reducing agent, tetrahedral intermediate was formed, as noted by peaks shifted down field 
with respect to their original spectra.  Lactonization profiles of Q-ETA compounds revealed 
different lifetimes, indicating that 3ʹ quinone substitution can be utilized to tune the rate of 
lactonization.  In D2O, upon addition of the reducing agent (Na2S2O4), QBr-ETA, QNMe-ETA, and 
QNPr-ETA lactonized rapidly, while QH-ETA showed a much slower intramolecular cyclization.  
The rapid lactonization behavior for QBr-ETA can be attributed to the electron withdrawing 
nature of bromine, while for the others, the internal base catalysis behavior of N-propylamino 
and N-methylamino nitrogen atom accelerated the cyclization.8  The rate for QMe-ETA was 
moderate and the rate constant (k) and half life (t1/2) were calculated successfully.  
The rate of lactonization of QMe-ETA was found to vary with temperature, buffer, and 
solvent conditions.  The existence of buffer conditions and increasing temperature accelerated 
cyclization, whereas the presence of organic solvent made the lactonization slower, caused by 
enhanced stability of the tetrahedral intermediate.  The QMe-COOH cyclization was much faster 
compared to the QMe-ETA derivative, due to its autocatalysis behavior.  Inclusion of secondary 
amide structures with the NMe functionality shows that the cyclization process was retarded 
compared to simple amide structures.  
These findings are supported by previous electrochemical and liposome payload release 
studies.8,30  Careful selection of quinone-amide structures and experimental conditions can be 
utilized to optimize the liposome system for future applications. 
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Table 3.3: Summary of kinetic Evaluation.  
 
*Note: All reactions were conducted in 25 ° C except as noted. 
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CONCLUSIONS AND OUTLOOK 
4.1 Summary 
The overall goal of this research was to investigate the kinetics of reduction and 
lactonization of trimethyl-lock quinone propionic acids and their amide derivatives, in order to 
optimize our recently developed redox-active liposome drug delivery system.1-3  Upon 
interaction with a redox stimulus, trimethyl-lock quinone head groups undergo intramolecular 
lactonization to initiate liposomal disintegration.  Thus, evaluation of lactonization kinetics with 
respect to diverse quinone-amide structures and experimental conditions is important, because 
the outcomes can be used to tailor the liposomal payload release.  
Seven different trimethyl-lock quinone propionic acid derivatives were synthesized by 
varying either the amide structure or the 3′ functionality of the quinone head group: QMe-ETA, 
QBr-ETA, QNMe-ETA, QNPr-ETA, QH-ETA, QMe-MeETA, and QMe-NMeBnOH.  The synthesis of 
quinone-amide followed a similar procedure where they were prepared from corresponding N-
hydroxysuccinimide derivative and were obtained in good yield.  These quinone-amides were 
then subjected to chemical reduction, and their lactonization behavior was followed by 1H NMR 
spectroscopy.  The gem-dimethyl integrals were used to evaluate the kinetics, and it was found 
that lactonization was much slower compared to the reduction.  Lactonization occurred through 
tetrahedral intermediate collapse and followed first order kinetics.  Initially, lactonization 
behavior of different Q-ETA compounds were studied in D2O; from fastest to slowest, the 
average lifetime values for complete lactonization are as follows: QNMe-ETA (3 min), QNPr-ETA 
(3 min), QBr-ETA (5 min), QMe-ETA (170 min) and QH-ETA (> 6 hours).  From these results, it 
is evident that the 3′ functionality of the quinone ring does affect the lactonization and these can 
be selectively incorporated to liposome systems to control their payload release. 
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Because QMe-ETA has shown measurable lactonization profile, its rate constant k: 0.023 
min-1 and t1/2 of 30 were calculated and employed for further studies.  In organic/aqueous 
medium (DMSO:D2O), it was found that the tetrahedral intermediate was somewhat stable after 
its formation from reduction, resulting in a 9 times slower lactonization when compared to 100% 
aqueous conditions.  Increasing the experimental temperature enhanced the rate of lactonization 
(at 35 °C, k = 0.046 min-1 and t1/2 = 15) whereas lowering the temperature created hostile 
conditions for the process and the reaction continued for an extended period of time (at 10 °C, k 
= 0.0061 min-1 and t1/2 = 1.1× 102).  Experiments in buffer environment also exhibited 
accelerated lactonization.  However, alteration of buffer pD from 7.21 to 7.41 did not 
significantly influence the lactonization rate constant.   
After identifying the behavior of Q-ETA derivatives, research was focused toward the 
investigation of the cyclization nature of other quinone propionic amide derivatives: QMe-
MeETA, QMe-NMeBnOH and QMe-NN.  Interestingly, in organic medium (DMSO:D2O = 5:2), 
the tetrahedral intermediate of both QMe-NMeBnOH and QMe-NN were stable for more than 1 
hour, resulting in an extremely slower lactonization where the process took more than 24 hours 
to complete.  Finally, to assess the effect of the secondary amide functionality in the amide 
structure, kinetic study on QMe-MeETA was performed in D2O medium, and it was observed that 
the rate constant for lactonization was 2 times slower when compared to the QMe-ETA 
derivative. 
4.2 Conclusion 
The results presented in this thesis demonstrate the capability of tuning the lactonization 
process of trimethyl-lock quinone propionic acid derivatives upon interaction with a redox 
stimulus.  Synthesis of quinone-amide derivatives followed a common methodology and 
products were obtained in good yield.  With the addition of different substituents onto the 3′ 
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position of the quinone head group, lactonization rates were significantly varied, which was in 
agreement with previously studied liposome payload release profiles.2  The rate of lactonization 
was influenced by changes in temperature, buffer, and solvent conditions.  Tertiary quinone-
amide structures exhibited slower rates of lactonization while the opposite was observed with 
secondary structures.  Inclusion of the NMe functionality to the amide structure, slows down the 
lactonization process significantly.  Modification of trimethyl-lock quinone based liposomes 
through of tertiary amide structures enables to have slower payload release profiles which is 
highly important in chemotherapy.  
4.3 Outlook 
A growing number of stimuli-responsive liposomal formulations that can selectively 
deliver chemotherapeutics to the tumor site by taking advantage of over-expressed tumor 
reductive enzymes are becoming of great interest in modern drug delivery.4-6  To that end, redox-
responsive, quinone trimethyl-lock liposome (Q-DOPE) system has been developed where the 
liposomal destruction is initiated upon reduction and lactonization of the quinone head group.1-3 
According to the literature, most of the chemotherapeutic agents exhibit their maximum 
antitumor activity, when they are distributed slower to intermediate rates within the tumor site.7,8 
Thus, details provided in this thesis could be useful to design new Q-DOPE liposomes and 
quinone based prodrugs by incorporating proper trimethyl-lock quinone head group as well as 
modified amide structures in order to attain slower to medium rate of drug release.  In 1982, 
Cohen and Michael have shown that replacement of the methyl group at the 6′ position of the 
benzene ring with varying functionalities resulted in significant changes of lactonization rates for 
their 4,4–dimethyl–6–hydroxyhydrocoumarrins compounds.9  Moreover, Jung and Piizzi pointed 
out the feasibility of lactonization of Potassium ω-Bromoalkanoate with bulky gem-dialkyl 
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groups.10  Thus, it is important to investigate the feasibility of lactonization of quinone-amides 
having different gemdialkyls as well as different functional groups at 6′ position in order to 
develop new liposome formulations having enhanced pharmacokinetics.  Furthermore, the results 
of this study can be used to develop other stimuli-sensitive trimethyl-lock systems (sensors, 
microfludic channels etc) to obtain an efficient cargo delivery. 
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